Search Bar & Filters
Found 39 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are studying the effects of anifrolumab in Chinese adults aged 18 to 70 with active moderate to severe systemic lupus erythematosus SLE. The study aims to describe clinical outcomes focusing on remission and evaluates a systematic approach to reduce glucocorticoid GC use to minimize exposure. This phase 3b, open-label, single-arm trial collects safety, efficacy, and patient-reported outcomes in this population following current standard-of-care guidelines. Participants will receive a fixed intravenous dose of anifrolumab administered via infusion pump over at least 30 minutes every 4 weeks for a total of 13 doses from Week 0 to Week 48, alongside their stable standard treatments, which may include glucocorticoids, antimalarials, or immunosuppressants. The dosing schedule requires at least 14 days between doses, with the primary evaluation taking place at Week 52. During the study, participants will undergo regular assessments including disease activity indices, joint and skin evaluations, laboratory tests, and quality-of-life questionnaires at multiple timepoints up to Week 52. Researchers will monitor remission rates, glucocorticoid tapering success, flare rates, immune markers, and safety parameters. The total study duration for each participant is approximately one year, with detailed evaluations to understand the treatments impact on disease control and steroid reduction.
Actively Recruiting
Researchers are studying the efficacy and safety of rilvegostomig combined with gemcitabine plus cisplatin compared to durvalumab combined with the same chemotherapy as first-line treatment for patients with advanced biliary tract cancer BTC. This Phase III, randomized, open-label study aims to evaluate these treatments in patients with unresectable locally advanced or metastatic BTC, including intra-hepatic or extra-hepatic cholangiocarcinoma and gallbladder carcinoma. Participants receive either rilvegostomig or durvalumab intravenously, both alongside gemcitabine and cisplatin chemotherapy. Durvalumab is given at 1500 mg IV every 3 weeks for up to 8 cycles, then every 4 weeks. Rilvegostomig is administered IV every 3 weeks. The chemotherapy regimen consists of gemcitabine 1000 mgm2 plus cisplatin 25 mgm2 on Day 1 and Day 8 of each 21-day cycle. Treatment continues according to the study protocol with close monitoring. During the study, participants undergo assessments including tumor measurements by CT or MRI using RECIST 1.1 criteria, evaluation of PD-L1 status, and performance status checks. Researchers also monitor overall survival and progression-free survival for up to approximately four years, as well as safety, tolerability, pharmacokinetics, and patient-reported symptoms and quality of life. Follow-up continues up to 12 weeks after disease progression for additional evaluations.
Actively Recruiting
Researchers are evaluating the addition of Tersolisib LY4064809STX-478 to other anti-cancer drugs as a first treatment for adults with advanced hormone receptor-positive HR and human epidermal growth factor receptor 2-negative HER2- breast cancer that has a PIK3CA genetic mutation. The study aims to assess the effectiveness and safety of this combination in people whose cancer cannot be cured by surgery alone. Participants may continue in the study as long as the treatment is helping and side effects are manageable. Participants will be randomly assigned to one of three groups two different doses of Tersolisib combined with a CDK46 inhibitor and endocrine therapy ET, or a placebo combined with the same drugs. The CDK46 inhibitor and ET are given orally or intramuscularly depending on the drug chosen by the investigator. Treatments are administered orally or by injection as appropriate. The study includes a phase 2 dose optimization portion and a phase 3 randomized, double-blind, placebo-controlled portion. During the study, participants will undergo regular assessments including scans and tests to measure tumor response and progression. Researchers will monitor overall response rate, progression-free survival, and other health outcomes for up to 5 to 7 years. Safety and drug levels in the blood will also be tracked. Participants quality of life and physical function will be evaluated using questionnaires. The total time in the study depends on individual treatment response and side effects.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of YL202 combined with other anti-tumor therapies in patients with advanced solid tumors. This multi-center, open-label phase IbII study focuses on patients with conditions such as advanced solid tumors, breast cancer, and non-small cell lung cancer, aiming to understand how these combinations work together in treating these cancers. The study has multiple parts Parts 1 and 3 involve YL202 given intravenously with Toripalimab injection, including dose escalation and expansion stages where doses are adjusted and optimized. Parts 2 and 4 include YL202 intravenously combined with oral Furmonertinib Mesilate tablets, also in dose escalation and expansion phases. Participants receive escalating doses of YL202 alongside fixed doses of the other drugs to determine the best treatment levels. Participants will undergo monitoring for dose-limiting toxicities within 21 days after the first dose and adverse events for 42 days after treatment ends. The study also tracks tumor response, drug pharmacokinetics, and immune reactions for up to about three years. Throughout the trial, patients will have regular visits for assessments, tumor evaluations, and safety checks to understand treatment effects and tolerability over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the effectiveness of a single dose of baloxavir marboxil compared with a placebo for preventing influenza virus infection in people who live with someone diagnosed with influenza. This study focuses on household contacts of influenza patients and aims to reduce symptomatic, laboratory-confirmed influenza cases. It is a Phase III, randomized, double-blind, placebo-controlled trial involving participants aged 5 years and older. Participants who live with an influenza patient will receive either baloxavir marboxil or a matching placebo based on their body weight. The influenza patients themselves will not receive the study drug but will continue their usual standard of care treatment. The study uses a parallel design to compare outcomes between these groups during the prevention period. Throughout the study, participants will be monitored from Day 1 up to Day 10 for influenza infection confirmed by laboratory tests and symptoms such as fever and respiratory issues. Researchers will also track adverse events for up to 21 days. Participants will keep symptom diaries if age-appropriate, and COVID-19 testing will be performed to exclude those with infection. The study completion is expected by April 2027.
Actively Recruiting
Researchers are evaluating the long-term safety, effectiveness, and breakdown of RADIESSE Injectable Implant for treating moderate to severe nasolabial folds NLFs in Chinese adults. The study focuses on confirming how well this implant improves wrinkle severity and overall aesthetic appearance over time. Participants will receive a single injection of RADIESSE into both nasolabial folds on the first day. At the investigators discretion, an optional touch-up injection may be given one month later. The treatment follows current product guidelines and instructions. After the last treatment, participants will be monitored for up to 24 months. During the study, participants will be assessed using scales that measure wrinkle severity and aesthetic improvement, both by the investigator and by the participant. The primary outcome is the percentage of participants achieving at least a one-point improvement in wrinkle severity six months after the last treatment. Safety and effectiveness will be closely tracked throughout the follow-up period.
1-10 of 39
1